PDCD1 and hepatocellular carcinoma: Therefore, a PEGylated IFN-α therapy with both anti-cancer and anti-HBV activities with the ability to enhance the anti-PD1-induced antitumor effect may reduce the need for anti-PD1 treatment at a high dose level when inhibiting HCC recurrence.